234 filings
8-K
CASI
CASI Pharmaceuticals Inc
21 Mar 23
Submission of Matters to a Vote of Security Holders
4:41pm
8-K
CASI
CASI Pharmaceuticals Inc
31 Jan 23
Entry into a Material Definitive Agreement
4:01pm
8-K
CASI
CASI Pharmaceuticals Inc
14 Nov 22
Casi Pharmaceuticals Announces Third Quarter 2022 Financial Results
4:00pm
8-K
CASI
CASI Pharmaceuticals Inc
23 Sep 22
Casi Pharmaceuticals Announces Exit of Juventas Investment to Strengthen Balance Sheet
4:02pm
8-K
CASI
CASI Pharmaceuticals Inc
12 Aug 22
Casi Pharmaceuticals Announces Second Quarter 2022 Financial Results
4:01pm
8-K
svfi8xt2
26 May 22
Casi Pharmaceuticals Announces Reverse Stock Split
4:40pm
8-K
qk62winf8u
25 May 22
Other Events
4:11pm
8-K
x2ls6a3vq7m8v bi47
25 May 22
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
usr99jtv9d3 dbjn7l6i
24 May 22
Entry into a Material Definitive Agreement
4:12pm
8-K
jj3mvkwc6o ds
24 May 22
Casi Pharmaceuticals Enters into Sublicense Agreement
4:01pm
8-K
j4hgfl80t6gjcy2o
12 May 22
Casi Pharmaceuticals Announces First Quarter 2022 Financial Results
4:30pm
8-K
ci96e0lom2
2 May 22
Other Events
4:01pm
8-K
5352xerijf3qyzhk2rul
28 Mar 22
Casi Pharmaceuticals Announces Full-year 2021 Financial Results and Fourth Quarter 2021 Evomela® Revenue
4:31pm
8-K
r8hcfs4ddpzo7zbgx339
4 Mar 22
Casi Pharmaceuticals Announces Renewal of Exclusive Distribution Agreement for Evomela® In China
8:03am
8-K
ph96 3uu43cuttnjrua3
16 Feb 22
Casi Pharmaceuticals Announces Preliminary Fourth Quarter and Full-year 2021 Revenues and Provides Business Updates
7:09am
8-K
fp0n0hwdmgh2l
3 Jan 22
Casi Pharmaceuticals, Receives Nasdaq Deficiency Notice
7:00am
8-K
5val2kck zlq5
17 Dec 21
Casi Pharmaceuticals Announces Stock Repurchase Program
7:12am
8-K
b2itnezkqfu2b
10 Dec 21
Departure of Directors or Certain Officers
4:01pm
8-K
v9hv4jesb6 6yosq2
12 Nov 21
Casi Pharmaceuticals Announces Third Quarter 2021 Financial Results
4:30pm
8-K
vdyble o7xun
29 Oct 21
Entry into a Material Definitive Agreement
4:10pm